Wright Medical Group WMGI and BioMimetic Therapeutics,
BMTI announced today that they have entered into a
definitive agreement for a business combination of Wright and
BioMimetic, both publicly traded, Tennessee-based companies. Wright is
an orthopedics company with a market-leading lower extremities
franchise. BioMimetic is focused on developing regenerative medicine
products to promote the healing of musculoskeletal injuries and diseases
with a novel protein therapeutic product, Augment® Bone
Graft, under late stage FDA review as a replacement for autologous bone
graft in foot and ankle fusions. The transaction will combine
BioMimetic's breakthrough biologics platform and pipeline with Wright's
established sales force and product portfolio, to further accelerate
growth opportunities in
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in